Professor John Radford is a Professor of Medical Oncology at The Christie NHS Foundation Trust in Manchester. The Christie identifies lymphoma as his principal specialty and lists him as Director of Research. His professional work has a long-standing focus on Hodgkin and non-Hodgkin lymphoma and on improving treatment outcomes for people living with cancer.

Lymphoma encompasses a diverse group of cancers affecting the lymphatic system. Because different lymphoma types behave differently, diagnosis and treatment planning require specialist assessment. Depending on the individual diagnosis, treatment may include chemotherapy, antibody-based therapies, targeted medicines, radiotherapy, stem-cell transplantation or other specialist approaches.

Professor Radford's research has included the development of evidence around PET scan-directed therapy in Hodgkin lymphoma. Positron emission tomography can provide information about how a lymphoma responds to treatment and may contribute to treatment planning in selected clinical situations.

The Christie also identifies Professor Radford with the clinical development of brentuximab vedotin. His work has therefore contributed to the wider research environment surrounding modern lymphoma treatment and clinical evidence.

Another important aspect of his work concerns long-term treatment effects. Cancer survivors can experience health issues years after treatment, making survivorship and late-effect management important components of modern oncology. Professor Radford has worked on reducing late treatment toxicity, including research concerning second cancers following lymphoma treatment.

He has also contributed to research infrastructure and digital health initiatives. The Christie states that he has served as Director of Research since 2007 and has supported development of the organisation's research environment. His responsibilities include leadership connected with the Centre for Living Beyond Cancer Science.

For patients seeking specialist lymphoma care in Manchester, Professor Radford's profile is relevant to medical oncology, Hodgkin lymphoma, non-Hodgkin lymphoma and cancer research. Patients are normally assessed according to their diagnosis, disease characteristics, previous treatment and overall health.

International patients considering treatment in the United Kingdom should prepare relevant medical documentation, including pathology results, imaging, treatment history and laboratory information where available. The specialist team can then determine the appropriate referral and assessment pathway.

Clinical research is another important part of The Christie's cancer services. Research studies can investigate new medicines, treatment combinations, diagnostic methods, survivorship approaches and digital healthcare systems. Eligibility varies from one study to another and should be confirmed directly with the research team.

Professor Radford has also published extensively in oncology and lymphoma research. The Christie reports more than 400 academic papers and significant research activity associated with his career. These publications form part of the scientific literature surrounding lymphoma treatment and cancer survivorship.

His role as Director of Research also demonstrates the connection

between patient care and research at The Christie. Specialist cancer centres frequently combine clinical services with academic research, allowing clinicians and scientists to investigate new approaches while continuing to provide established treatments.

For an SEO-focused medical directory, Professor John Radford's profile can appropriately target terms including lymphoma specialist, medical oncologist, Hodgkin lymphoma treatment, non-Hodgkin lymphoma, cancer research and The Christie Manchester.

Patients should not interpret an individual doctor's research interests as a recommendation for a particular treatment. The appropriate treatment depends on the individual diagnosis and should be discussed with the patient's treating oncology team.

Professor John Radford's current position and responsibilities are documented on The Christie's consultant profile, making him a relevant consultant to include in a specialist cancer directory focused on Manchester and the United Kingdom.